Floatz Rating
CCC51/100
Confidence
Indicative
Sponsor
Bristol-Myers Squibb
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
44High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05688475CT.gov A Rollover Study of CC-122 | — | Active Not Recruiting | — | — | — |
NCT03310619CT.gov A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies | — | Completed | — | — | — |
NCT02509039CT.gov A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL) | — | Terminated | — | — | — |
NCT02417285CT.gov A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL. | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Hodgkin Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Avadomide (this asset) | Bristol-Myers Squibb | P1/2 | CCC · 51 |
| Cyclosporin A | Memorial Sloan Kettering Cancer Center | P3 | BBB |
| Pegaspargase | Ciusss de L'Est de l'Île de Montréal | P4 | BBB |
| Adriamycin | National Cancer Institute (NCI) | P4 | BBB |
| Prednisolone | Mwanasha Merrill, MD | P3 | BBB |
| Entecavir | Fudan University | P4 | BBB |
| Cyclophosphamide | National Cancer Institute (NCI) | P4 | BBB |
| Rituximab | National Cancer Institute (NCI) | P4 | BBB |
| Prednisone | National Cancer Institute (NCI) | P3 | BBB |
+42 more in the Non-Hodgkin Lymphoma cohort
Other indications for Avadomide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Diffuse Large B-Cell Lymphoma | — | P1/2 | CCC · 55 |
| Hepatocellular Carcinoma | — | P1/2 | CCC · 51 |
| Follicular Lymphoma | — | P1/2 | CCC · 50 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Avadomide in Non-Hodgkin Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/avadomide-non-hodgkin-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →